Recursion (RXRX) Q3 2026 Earnings Call Transcript
Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.
How this was made

The 30-second read
Why it matters
The disclosed data and financing could drive short-term price movement and influence biotech sector sentiment.
Market read
Recursion's new data and capital raise provide fresh material for traders, with potential upside in the biotech space.
What to watch
Potential regulatory hurdles for the new oral small molecule and execution risk on upcoming Phase I trials.
Background
Recursion presented early clinical results, partnership milestones, and financial updates during its Q3 2026 earnings call.
Ticker impact
Recursion's Q3 2026 earnings call disclosed updated clinical data for programs REC-4881 and REC-1245, a $200M financing, lowered 2026 expense guidance, and a new board chair appointment.
likely upward pressure as investors price in new data and financing
New trial data and a sizable financing round are fresh material that can move the stock, and expense guidance reduction improves outlook.
Market effects
Highlights AI-driven drug discovery progress, potentially boosting biotech sector sentiment.
US biotech investors may react; limited immediate impact on broader markets.
Shows growing partnership activity with global pharma firms (Sanofi, Roche).
Counterpoint
If the clinical data fails to translate into later-stage success, the financing may dilute existing shareholders.
Key entities
- CompanyRecursion Pharmaceuticals
Biotech firm focused on AI-driven drug discovery.



